Peripheral Blood CD8+ Cytotoxic T Cells, Frozen
Human peripheral blood CD8+ cytotoxic T cells are enriched by depleting cells expressing CD4, CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD61, CD123, TCRγ/δ, and CD235a from the mononuclear cell population using immunomagnetic particles leaving purified, untouched CD8+ cytotoxic T cells. Isolated cells are characterized by flow cytometry to ensure a highly pure and viable cell population.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies. By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.

Description
Human CD8+ cytotoxic T cells, also known as cytotoxic T lymphocytes, defend the body against intracellular pathogens, such as viruses and bacteria, as well as cancerous cells. CD8+ T cells distinguish infected or diseased cells from healthy cells by recognizing antigens presented by MHC class I molecules located on the surface of the inflicted cells. Once the CD8+ T cells recognize a specific antigen it releases cytotoxins that result in apoptosis of the infected or diseased cell.
Additional information
Anticoagulant | |
---|---|
Format | |
Grade | |
Species | |
Cell and Tissue Source | |
Disease State | |
Donor Attributes |